BeOne Medicines (BEIGF) Profit After Tax (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Profit After Tax data on file, last reported at $227.4 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at $227.4 million, up 17802.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $513.0 million (up 230.75% YoY), and the FY2025 annual result was $286.9 million, up 144.5% from the prior year.
• Profit After Tax rose to $227.4 million in Q1 2026 per BEIGF's latest filing, from $66.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at $227.4 million in Q1 2026 and troughed at -$565.7 million in Q2 2022.
• A 5-year average of -$177.4 million and a median of -$151.9 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax plunged 754.48% in 2022, then surged 17802.13% in 2026.
• A 5-year view of Profit After Tax shows it stood at -$445.3 million in 2022, then advanced by 17.47% to -$367.6 million in 2023, then jumped by 58.68% to -$151.9 million in 2024, then jumped by 143.79% to $66.5 million in 2025, then surged by 241.88% to $227.4 million in 2026.
• Business Quant data shows BEIGF's Profit After Tax at $227.4 million in Q1 2026, $66.5 million in Q4 2025, and $124.8 million in Q3 2025.